Endocrine sequelae of cancer and cancer treatments

Journal of Cancer Survivorship

Volumn 1, Issue 4, 2007, Pages 261-274

  Stava, Charles J ^a   Jimenez, Camilo ^a   Vassilopoulou Sellin, Rena ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adverse effects; Antineoplastic agents; Chemically induced; Complications; Drug effects; Endocrine system; Endocrine system diseases; Late effects; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ADRENAL DISEASE; ARTICLE; DIABETES INSIPIDUS; FEMALE; GONADAL DISEASE; HEALTH STATUS; HUMAN; HYPOPITUITARISM; HYPOTHALAMUS DISEASE; MALE; METABOLIC DISORDER; NEOPLASM; PARATHYROID DISEASE; PATHOPHYSIOLOGY; RADIOTHERAPY; SURVIVOR; THYROID DISEASE;

ADRENAL GLAND DISEASES; ANTINEOPLASTIC AGENTS; DIABETES INSIPIDUS; FEMALE; GONADAL DISORDERS; HEALTH STATUS; HUMANS; HYPOPITUITARISM; HYPOTHALAMIC DISEASES; MALE; METABOLIC DISEASES; NEOPLASMS; PARATHYROID DISEASES; RADIOTHERAPY; SURVIVORS; THYROID DISEASES;

EID: 36749092773     PISSN: 19322259     EISSN: 19322267     Source Type: Journal    
DOI: 10.1007/s11764-007-0038-6     Document Type: Article

References (184)

1. Hewitt M, Greenfield S, Stovall E. From cancer patient to cancer survivor lost in transition. 1st ed. Washington, DC: National Academies; 2006.
2. Stava C, Beck M, Schultz PN, Vassilopoulou-Sellin R. Hearing loss among cancer survivors. Oncol Rep 2005;13:1193-9.
3. Stava C, Beck M, Vassilopoulou-Sellin R. Cataracts among cancer survivors. Am J Clin Oncol 2005;28:603-8.
4. Schultz PN, Stava C, Beck ML, Vassilopoulou-Sellin R. Ethnic/racial influences on the physiologic health of cancer survivors. Cancer 2004;100:156-64.
5. Stava CJ, Lopez A, Vassilopoulou-Sellin R. Health profiles of younger and older breast cancer survivors. Cancer 2006;107:1752-9.
6. Stava C, Weiss LT, Vassilopoulou-Sellin R. Health profiles of 814 very long-term breast cancer survivors. Clin Breast Cancer 2006;7:228-36.
7. Schultz PN, Klein MJ, Beck ML, Stava C, Sellin RV. Breast cancer: relationship between menopausal symptoms, physiologic health effects of cancer treatment and physical constraints on quality of life in long-term survivors. J Clin Nurs 2005;14:204-11.
8. Stava C, Beck M, Lopez A, Vassilopoulou-Sellin R. Health Profiles of 996 Melanoma Survivors: the MD Anderson Experience. BMC Cancer 2006;6:95.
9. Stava C, Beck ML, Feng L, Lopez A, Busaidy N, Vassilopoulou-Sellin R. Diabetes mellitus among cancer survivors. J Can Surviv 2007;1:102-115.
10. Schultz PN, Stava C, Vassilopoulou-Sellin R. Health profiles and quality of life of 518 survivors of thyroid cancer. Head Neck 2003;25:349-56.
11. Cohen LE. Endocrine late effects of cancer treatment. Endocrinol Metab Clin North Am 2005;34:769-89.
12. Yeung SC, Chiu AC, Vassilopoulou-Sellin R, Gagel RF. The endocrine effects of nonhormonal antineoplastic therapy. Endocr Rev 1998;19:144-172.
13. Brougham MFH, Kelnar CJH, Wallace WHB. The late endocrine effects of childhood cancer treatment. Pediatr Rehab 2002;5:191-201.
14. Sklar CA. Overview of the effects of cancer therapies; the nature, scale and breadth of the problem. Acta Paediatr Suppl 1999;88:1-4.
15. Van Santen HM, de Kraker K, Vulsma T. Endocrine late effects from mult-modality treatment of neuroblastoma. Eur J Cancer 2005;41:1767-74.
16. Rose SR, Schreiber RE, Kearney NS, Lustig RH, Danish RK, Burghen GA, et al. Hypothalamic dysfunction after chemotherapy. J Pediatr Endocrinol Metab 2004;17:55-66.
17. Kaltsas GA, Mukherjee JJ, Plowman PN, Monson JP, Grossman AB, Besser GM. The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. J Clin Endocrinol Metab 1998;83:4233-38.
18. Toogood AA. Endocrine consequences of brain irradiation. Growth Horm IGF Res 2004;14(Suppl A):S118-24.
19. Agha A, Sherlock M, Brennan S, O, Connor SA, O, Sullivan E, Rogers B, et al. Hypothalamic-pituitary dysfunction after irradiation of non-pituitary brain tumors in adults. J Clin Endocrinol Metab 2005;90:6355-60.
20. Concha LB, Carlson HE, Heimann A, Lake-Bakaar GV, Paal AF. Interferon-induced hypopituitarism. Am J Med 2003;114:161-3.
21. Chan WB, Cockram CS. Panhypopituitarism in association with interferon-alpha treatment. Singap Med J 2004;45:93-4.
22. Langsenlehner T, Stiegler C, Quehenberger F, Feigl GC, Jakse G, Mokry M, et al. Long-term follow up of patients with pituitary macroadenomas after postoperative radiation therapy: analysis of tumor control and functional outcome. Strahlenther Onkol 2007;183:241-7.
23. Minniti G, Jaffrain-Rea M, Osti M, Esposito V, Santoro A, Solda F, et al. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol 2005;62:210-6.
24. Oberfield SE, Nirenberg A, Allen JC, Cohen H, Donahue B, Prasad V, et al. Hypothalamic-pituitary-adrenal function following cranial irradiation. Horm Res 1997;47:9-16.
25. Spoudeas HA, Charmandari E, Brook CG. Hypothalamo-pituitary-adrenal axis integrity after cranial irradiation for childhood posterior fossa tumours. Med Pediatr Oncol 2003;40:224-9.
26. Sorensen JB, Andersen MK, Hansen HH. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med 1995;238:97-110.
27. Ishii K, Aoki Y, Sasaki M, Tanaka K. Syndrome of inappropriate secretion of antidiuretic hormone induced by intraarterial cistplatin therapy. Gynecol Oncol 2002;87:150-1.
28. Kusuki M, Iguchi H, Nakamura A, Nishiura H, Kanazawa A, Yamane H. The syndrome of inappropriate antidiuretic hormone secretion associated with chemotherapy for hypophayryngeal cancer. Acta Otolaryngol Suppl 2004;554:74-7.
29. Yamomoto Y, Kokubo A, Yonekawa M, Nakanishi K. Syndrome of inappropriate secretion of antidiuretic hormone suddenly occurring in a case following chemotherapy. Gan To Kagaku Ryoho 2005;32:107-9.
30. Otsuka F, Hayashi Y, Ogura T, Hayakawa N, Ikeda S, Makino H, et al. Syndrome of inappropriate secretion of antidiuretic hormone following intrathoracic cisplatin. Intern Med 1996;35:290-4.
31. Robinson C, Jeffries RC, Walsh GC. Inappropriate ADH secretion caused by oat cell carcinoma and relieved by lung resection. Thorax 1980;35:635-7.
32. Negro A, Regolisti G, Perazzoli F, Davili S, Sani C, Rossi E. Ifosfamide-induced renal Franconi syndrome with associated nephrogenic diabetes insipidus in an adult patient. Nephrol Dial Transplant 1998;13:1547-9.
33. Rossi R, Gödde A, Kleinebrand A, Rath B, Jürgens H. Concentrating capacity in ifosfamide-induced severe renal dysfunction. Ren Fail 1995;17:551-7.
34. Sinner R, Pearson AD, English MW, Price L, Wyllie RA, Coulthard MG, et al. Risk factors for ifosfamide nephrotoxicity in children. Lancet 1996;348:578-80.
35. Murray-Lyon IM, Cassar J, Coulson R, Williams R, Ganguli PC, Edwards JC, et al. Further studies on streptozotocin therapy for a multiple-hormone producing islet cell carcinoma. Gut 1971;12:717-20.
36. Delaney V, de Pertuz Y, Nixon D, Bourke E. Indomethacin in streptozocin-induced nephrogenic diabetes insipidus. Am J Kidney Dis 1987;9:79-83.
37. Gleeson HK, Shalet SM. The impact of cancer therapy on the endocrine system in survivors of childhood brain tumors. Endocr Relat Cancer 2004;11:589-602.
38. Borson-Chazot F, Brue T. Pituitary deficiency after brain radiation therapy. Ann Endocrinol (Paris) 2006;67:303-9.
39. Bhansali A, Banerjee AK, Chanda A, Singh P, Sharma SC, Mathuriya SN, et al. Radiation-induced brain disorders in patients with pituitary tumors. Australas Radiol 2004;48:339-46.
40. Jyotsna VP, Singh SK, Chaturvedi R, Neogi B, Bhadada SK, Sahay RK, et al. Cranial irradiation- an unusual case for diabetes insipidus. J Assoc Physicians India 2000;48:1107-8.
41. Murray RD, Brennan BM, Rahim A, Shalet SM. Survivors of childhood cancer: long-term endocrine and metabolic problems dwarf the growth disturbance. Acta Paediatr Suppl 1999;88:5-12.
42. Román J, Villaizán CJ, García-Foncillas J, Azcona C, Salvador J, Sierrasesúmaga L. Chemotherapy-induced growth hormone deficiency in children with cancer. Med Pediatr Oncol 1995;25:90-5.
43. Olshan JS, Gubernick J, Packer RJ, D, Angio GJ, Goldwein JW, Willi SM, et al. The effects of adjuvant chemotherapy on growth in children with medulloblastoma. Cancer 1992;70:2013-7.
44. Marky I, Mellander L, Lannering B, Albertsson-Wikland L. A longitudinal study of growth and growth hormone secretion in children during treatment for acute lymphoblastic leukemia. Med Pediatr Oncol 1991;19:258-64.
45. Brennan BM, Rahim A, Mackie EM, Eden OB, Shalet SM. Growth hormone status in adults treated for acute lymphoblastic leukemia in childhood. Clin Endocrinol (Oxf) 1998;48:777-83.
46. Hameed R, Zacharin MR. Long-term endocrine effects of cancer treatment: experience of the Royal Children's Hospital Melbourne. J Paediatr Child Health 2005;41:36-42.
47. Livesey EA, Hindmarsh PC, Brook CG, Whitton AC, Bloom HJ, Tobias JS, et al. Endocrine disorders following treatment for childhood brain tumours. Br J Cancer 1990;61:622-5.
48. Karasek M, Pawlikowski M, Lewinski A. Hyperprolactinemia: causes, diagnosis, and treatment. Endokrynol Pol 2006;57:656-62. (article in Polish).
49. Darzy KH, Shalet SM. Hypopituitarism as a consequence of brain tumors and radiotherapy. Pituitary 2005;8:203-11.
50. Constine LS, Rubin P, Woolf PD, Doane K, Lush CM. Hyperprolactinemia and hypothyroidism following cytotoxic therapy for central nervous system malignancies. J Clin Oncol 1987;5:1841-51.
51. Constine LS, Woolf PD, Cann D, Mick G, McCormick K, Raubertas RF, et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Eng J Med 1993;328:87-94.
52. Ogilvy-Stuart AL, Shalet SM. Effect of radiation on the human reproductive system. Environ Health Perspect 1993;101(Suppl 2):109-16.
53. Yeung SJ, Gagel RF. Section 40. Complications of cancer and its treatment, 155. Endocrine complications. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Pollock RE, Weischselbaum RR, editors. Cancer medicine. 5th ed. Hamilton, Ontario, Canada: BC Decker Inc.; 2000.
54. Rappaport R, Brauner R, Czernichow P, Thibaud E, Renier D, Zucker JM, et al. Effects of hypothalamic and pituitary irradiation on pubertal development in children with cranial tumors. J Clin Endocrinol Metab 1982;54:1164-8.
55. Bartalena L, Martino E, Antonelli A, Pacchiarotti A, Robbins J, Pinchera A. Effect of the antileukemic agent l-asparaginase on thyroxine-binding globulin and albumin synthesis in cultured human hepatoma (HEP G2) cells. Endocrinology 1986;119:1185-8.
56. Surks MI, Sievert R. Drugs and thyroid function. N Engl J Med 1995;333:1688-94.
57. Dong BJ. How medications affect thyroid function. West J Med 2000;172:102-6.
58. Mamby CC, Love RR, Lee KE. Thyroid function test changes with adjuvant tamoxifen therapy in postmenopausal women with breast cancer. J Clin Oncol 1995;13:854-7.
59. Djurica SN, Plećas B, Milojević Z, Petrović M, Cirović M, Tasovac-Ponomarev D. Direct effects of cytostatic therapy on the functional state of the thyroid gland and TBG in serum of patients. Exp Clin Endocrinol 1990;96:57-63.
60. Paulino AC. Hypothyroidism in children with medulloblastoma: a comparison of 3600 and 2340 cGy craniospinal radiotherapy. Int J Radiat Oncol Biol Phys 2002;53:543-7.
61. Chianese-Bullock KA, Woodson EM, Tao H, Boerner SA, Smolkin M, Grosh WW, et al. Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2. J Immunother 2005;28:412-9.
62. Bohbot NL, Young J, Orgiazzi J, Buffet C, François M, Bernard-Chabert B, et al. Interferon-alpha-induced hyperthyroidism: a three-stage evolution from silent thyroiditis towards Graves' disease. Eur J Endocrinol 2006;154:367-72.
63. Kruit WH, Bolhuis RL, Goey SH, Jansen RL, Eggermont AM, Batchelor D, et al. Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response. J Clin Oncol 1993;11:921-4.
64. Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casari P, et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 2007;92:3531-4.
65. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007;99:81-3.
66. Wong F, Rosen LS, Mulay M, Vanvught A, Dinolfo A, Tomoda C, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007;17:351-5.
67. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006;145:660-4.
68. Maitland ML, Ratain MJ. Terminal ballistics of kinase inhibitors: there are no magic bullets. Ann Intern Med 2006;145:702-3.
69. Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006;42:3127-39.
70. Garfield DH, Hercbergs A, Davis PJ. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007;99:975-6.
71. Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 1999;340:1075-9.
72. Bessho R, Ohta K, Akanuma A, Sakata K. Dosimetry of radiation scattered to thyroid gland from prophylactic cranial irradiation for childhood leukemia. Pediatr Hematol Oncol 1994;11:47-53.
73. Madanat LM, Lahteenmaki PM, Alin J, Salmi TT. The natural history of thyroid function abnormalities after treatment for childhood cancer. Eur J Cancer 2007;43:1161-70.
74. Jereczek-Fossa BA, Alterio D, Jassem J, Gibelli B, Tradati N, Orecchia R. Radiotherapy-induced thyroid disorders. Cancer Treat Rev 2004;30:369-84.
75. Chin D, Sklar C, Donahue B, Uli N, Geneiser N, Allen J, et al. Thyroid dysfunction as a late effect in survivors of pediatric medulloblastoma/primitive neuroectodermal tumors: a comparison of hyperfractionated versus conventional radiotherapy. Cancer 1997;80:798-804.
76. Littley MD, Shalet SM, Morgenstern GR, Deakin DP. Endocrine and reproductive dysfunction following fractionated total body irradiation in adults. Quart J Med 1991;78:265-74.
77. Ishiguro H, Yasuda Y, Tomita Y, Shinagawa T, Shimizu T, Morimoto T, et al. Long-term follow-up of thyroid function in patients who received bone marrow transplantation during childhood and adolescence. J Clin Endocrinol Metab 2004;89:5981-6.
78. Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med 1991;325:599-605.
79. Loeffler JS, Tarbell NJ, Garber JR, Mauch P. The development of Graves' disease following radiation therapy in Hodgkin's disease. Int J Radiat Oncol Biol Phys 1988;14:175-8.
80. Jacobson DR, Fleming BJ. Grave's disease with ophthalmopathy following radiotherapy for Hodgkin's disease. Am J Med Sci 1984;288:217-20.
81. Al-Anazi KA, Inam S, Jeha MT, Judzewitch R. Thyrotoxic crisis induced by cytotoxic chemotherapy. Support Care Cancer 2005;13:196-8.
82. Kabbaj N, Guedira MM, El Atmani H, El Alaoui M, Mohammadi M, Benabed K, et al. Thyroid disorders during interferon alpha therapy in 625 patients with chronic hepatitis C: a prospective cohort study. Ann Endocrinol (Paris) 2006;67:343-7.
83. Umemoto S, Izumi K, Kanno H. Two cases of hyperthyroidism induced by interferon-alpha therapy for renal cell carcinoma. Hinyokika Kiyo 2007;53:225-9. (article in Japanese).
84. Sklar C, Whitton J, Mertens A, Stovall M, Green D, Marina N, et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the childhood cancer survivor study. J Clin Endocrinol Metab 2000;85:3227-32.
85. Nishiyama K, Kozuka T, Higashihara T, Miyauchi K, Okagawa K. Acute radiation thyroiditis. Int J Radiat Oncol Biol Phys 1996;6:1221-4.
86. Atsmon J, Dolev E. Drug-induced hypomagnesaemia: scope and management. Drug Safety 2005;28:763-88.
87. Elisaf M, Milionis H, Siamipoulos KC. Hypomagnesemic hypokalemia and hypocalcemia: clinical and laboratory characteristics. Miner Electrolyte Metab 1997;23:105-12.
88. Buckley JE, Clark VL, Meyer TJ, Pearlman NW. Hypomagnesemia after cisplatin combination chemotherapy. Arch Intern Med 1984;114:2347-8.
89. Stöhr W, Paulides M, Bielack S, Jürgens H, Koscielniak E, Rossi R, et al. Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system. Pediatr Blood Cancer 2007;48:140-7.
90. Lyman NW, Hemalatha C, Viscuso RL, Jacobs MG. Cisplatin-induced hypocalcemia and hypomagnesemia. Arch Intern Med 1980;140:1512-4.
91. Baeksgaard K, Sorensen JB. Acute tumor lysis syndrome in solid tumors-a case report and review of the literature. Cancer Chemother Pharmacol 2003;51:187-92.
92. Furue H. Interferons-its method of administration and adverse effect related to pharmacokinetics. Gan to Kagaku Ryoho 1984;11:186-93. (article in Japanese).
93. Tanvetyanon T, Choudhury AM. Hypocalcemia and azootemia associated with zoledronic acid and interferon alfa. Ann Pharmacother 2004;38:418-21. (Epub 2004 Jan 23).
94. Rosen IB, Strawbridge HG, Bain J. A case of hyperparathyroidism associated with radiation to the head and neck area. Cancer 1975;36:1111-4.
95. Stephen AE, Chen KT, Milas M, Siperstein AE. The coming of age of radiation-induced hyperparathyroidism: evolving patterns of thyroid and parathyroid disease after head and neck irradiation. Surgery 2004;136:1143-53.
96. Hedman I, Hansson G, Lundberg LM, Tisel LE. A clinical evaluation of radiation-induced hyperparathyroidism based on 148 surgically treated patients. World J Surg 1984;8:96-105.
97. Fiorica V, Males JL. Hyperparathyroidism after radiation of the neck: a case report and review of the literature. Am J Med Sci 1979;278:223-8.
98. Thorp MA, Levitt NS, Mortimore S, Isaacs S. Parathyroid and thyroid function five years after treatment of laryngeal and hypopharyngeal carcinoma. Clin Otolaryngol Allied Sci 1999;24:104-8.
99. Harvey PW, Everett DJ, Springall CJ. Adrenal toxicity: a strategy for assessment of functional toxicity to the adrenal cortex and steroidogenesis. J Appl Toxicol 2007;27:103-15.
100. Howard SC, Pui CH. Endocrine complications in pediatric patients with acute lymphoblastic leukemia. Blood Rev 2002;16:225-43.
101. Hahner S, Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs 2005;6:386-94.
102. van Ditzhuijsen CI, van der Weijer R, Haak HR. Adrenocorticol carcinoma. Neth J Med 2007;65:55-60.
103. Allolio B, Fassnacht M. Clinical review: Adrenocorticol carcinoma: clinical update. J Clin Endocrinol Metab 2006;91:2027-37.
104. Schteingart DE. Adjuvant mitotane therapy of adrenal cancer-use and controversy. N Engl J Med 2007;356:2415-8.
105. Smalley RV, Wall RL. Two cases of busulfan toxicity. Ann Intern Med 1966;64:154-64.
106. Ward HN, Konikov N, Reinhard EH. Cytologic dysplasia occurring after busulfan (Myleran) therapy. A syndrome resembling adrenocorticol insufficiency and atrophic bronchitis. Ann Intern Med 1965;63:654-60.
107. Kyle RA, Schwartz RS, Oliner HL, Dameshek W. A syndrome resembling adrenal corticol insufficiency associated with long term busulfan (Myleran) therapy. Blood 1961;18:497-510.
108. Harrold BP. Syndrome resembling Addison's disease following prolonged treatment with busulphan. Br Med J 1966;1:463-4.
109. GlaxoSmithKline. Myleran, Prescribing Information. Jan 2004. GlaxoSmithKline.
110. Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007;13:1367-73.
111. Kobayashi K, Weiss RE, Vogelzang NJ, Vokes EE, Janisch L, Ratain MJ. Mineralocorticoid insufficiency due to suramin therapy. Cancer 1996;78:2411-20.
112. Dorfinger K, Niederle B, Vierhapper H, Astrid W, Czernin S, Nowotny P, et al. Suramin and the human adrenocortex: results of experimental and clinical studies. Surgery 1991;110:1100-5.
113. Leinung MC, Liporace R, Miller CH. Induction of adrenal suppression by megestrol acetate in patients with AIDS. Ann Intern Med 1995;122:843-5.
114. Wingard JR, Vogelsang GB, Deeg HJ. Stem sell transplantation: supportive care and long-term complications. Hematology 2002;1:422-44.
115. Schmiegelow M. Endocrinological late effects following radiotherapy and chemotherapy of childhood brain tumours. Dan Med Bull 2006;53:326-41.
116. Stricker CT. Endocrine effects of breast cancer treatment. Sem Oncol Nurs 2007;23:55-70.
117. Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 2006;24:5769-79.
118. Wallace WH, Shalet SM, Crowne EC, Morris-Jones PH, Gattamaneni HR, Price DA. Gonadal dysfunction due to cis-platinum. Med Pediatr Oncol 1989;17:409-13.
119. Brydoy M, Fossa SD, Dahl O, Bjoro T. Gonadal dysfunction and fertility problems in cancer survivors. Acta Oncol 2007;46:480-9.
120. Viviani S, Santoro A, Ragni G, Bonfante V, Bestetti O, Bonadonna G. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs. ABVD. Eur J Cancer Clin Oncol 1985;21:601-5.
121. Howell S, Shalet S. Gonadal damage from chemotherapy and radiotherapy. Endocrinol Metab Clin North Am 1998;27:927-43.
122. Howell SJ, Radford JA, Ryder WD, Shalet SM. Testicular function after cytotoxic chemotherapy; evidence of Leydig cell insufficiency. J Clin Oncol 1999;17:493-8.
123. Gerl A, Muhlbayer D, Hansmann G, Mraz W, Hiddemann W. The impact of chemotherapy on Leydig cell function in long-term survivors of germ cell tumors. Cancer 2001;91:1297-1303.
124. Gleeson HK, Shalet SM. Endocrine complications of neoplastic diseases in children and adolescents. Curr Opin Pediatr 2001;13:346-51.
125. Howell SJ, Shalet SM. Spermatogenesis after cancer treatment: damage and recovery. J Natl Cancer Inst Monogr 2005;34:12-7.
126. Heikens J, Behrendt H, Adriaanse R, Berghout A. Irreversible gonadal damage in male survivors of pediatric Hodgkin's disease. Cancer 1996;78:2020-4.
127. Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996;14:2923-32.
128. Bramswig GL, Shlegel W, Jurgens H, Schellong G. The effects of etoposide on testicular function in boys treated for Hodgkin's disease. Cancer 1998;83:2217-22.
129. Wiechno P, Demkow T, Kubiak K, Sadowska M, Kaminska J. The quality of life and hormonal disturbances in testicular cancer survivors in cisplatin era. Eur Urol 2007;52:1448-54.
130. Berger CC, Bokemeyer C, Schuppert F, Schmoll HJ. Endocrinological late effects after chemotherapy for testicular cancer. Br J Cancer 1996;73:1108-14.
131. Arlt W, Hove U, Muller B, Reincke M, Berweiler U, Schwab F, et al. Frequent and frequently overlooked: treatment-induced endocrine dysfunction in adult long-term survivors of primary brain tumors. Neurology 1997;47:498-506.
132. Bryce CJ, Shenkier T, Gelmon K. Menstrual disruption in premenopausal breast cancer patients receiving CMF (IV) vs. AC adjuvant chemotherapy. Breast Cancer Res Treat 1998;50:284.
133. Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 2002;9:466-72.
134. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718-29.
135. Petrek JA, Naughton MJ, Case LD, Paskett ED, Naftalis EZ, Singletary SE, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006;24:1045-51.
136. Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 2002;9:466-72.
137. Knobf MT. The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. The Oncologist 2006;11:96-110.
138. Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol 2007;30:126-32.
139. Monga U. Sexual functioning in cancer patients. Sex Disabil 2002;20:277-95.
140. Tauchmanova L, Selleri C, DeRosa G, Pagano L, Orio F, Lombardi G, et al. High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. Cancer 2002;95:1076-84.
141. Thibaud E, Rodriguez-Macias K, Trivin C, Esperou H, Michon J, Brauner R. Ovarian function after bone marrow transplantation during childhood. Bone Marrow Transplant 1998;21:287-90.
142. Meistrich ML, Vassilopoulou-Sellin R, Lipschultz LI. Adverse effects of treatment: gonadal dysfunction. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer, principles and practice of oncology. 5th ed. New York: Lippincott-Raven; 1997. p. 2758-73.
143. Standeven AM, Beard RL, Johnson AT, Boehm MF, Escobar M, Heyman RA, et al. Retinoid-induced hypertriglyceridemia in rats is mediated by retinoic Acid receptors. Fundam Appl Toxicol 1996;33:264-72.
144. Dillman RO, Shea WM, Tai DF, Mahdavi K, Barth NM, Kharkar BR, et al. Interferon-alpha2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma. Neuro-Oncol 2001;3:35-41.
145. Rodondi N, Darioli R, Ramelet AA, Hohl D, Lenain V, Perdrix J, et al. High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic therapy for acne: a pharmacogenetic study. Ann Intern Med 2002;136:582-9.
146. Stoll D, Binnert C, Mooser V, Tappy L. Short-term administration of isotretinoin elevates plasma triglyceride concentrations without affecting insulin sensitivity in health humans. Metabolism 2004;53:4-10.
147. Hoffman-La Roche Inc. Roferon-A, Complete product information. Sept 2003.
148. Peñarrubia MJ, Steegmann JL, Lavilla E, Casado F, Requena MJ, Picõ M, et al. Hypertriglyceridemia may be severe in CML patients treated with interferon-alpha. Am J Hematol 1995;49:240-1.
149. Wong SF, Jakowatz JG, Taheri R. Management of hypertriglyceridemia in patients receiving interferon for malignant melanoma. Ann Pharmacother 2004;38:1655-9.
150. Raghavan D, Cox K, Childs A, Grygiel J, Sullivan D. Hypercholesterolemia after chemotherapy for testis cancer. J Clin Oncol 1992;10:1375-9.
151. Gietema JA, Sleijfer DT, Willemse PH, Scraffordt Koops H, van Ittersum E, Verschuren WM, et al. Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med 1992;116:709-15.
152. Fenton DW, Verma S, Venner P, Sawhney R, Mackey JR. The lack of long-term effect of cisplatin based combination chemotherapy on serum cholesterol for treatment of testicular cancer. J Urol 2002;168:1971-4.
153. Vassilopoulou-Sellin R, Samaan NA. Mitotane administration: an unusual cause of hypercholesterolemia. Horm Metab Res 1991;23:619-20.
154. Toma S, Bonelli L, Sartoris A, Mira E, Antonelli A, Beatrice F, et al. 13-cis Retinoic acid in head and neck cancer chemoprevention: results of a randomized trial from the Italian Head and Neck Chemoprevention Study Group. Oncol Rep 2004;11:1297-305.
155. Parsons SK, Skapek SX, Neufeld EJ, Kuhlman C, Young ML, Donnelly M, et al. Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Blood 1997;89:1886-95.
156. Maher VM, Trainer PJ, Scoppola A, Anderson JV, Thompson GR, Besser GM. Possible mechanism and treatment of o,p′DDD-induced hypercholesterolaemia. Q J Med 1992;84:671-9.
157. Lasa O, Izu R, Acebo E, Eguino P, Díaz-Pérez JL. Treatment of cutaneous T-cell lymphomas with bexarotene. Actas Dermo-sifiliogr 2006;97:102 (article in Spanish).
158. Lowe MN, Plosker GL. Bexarotene. Am J Clin Dermatol 2000;1:245-50. (discussion 251-2).
159. Zalewska-Szewczyk B, Przybysz K, Kowalewska-Pietrzak M, Stolarska M, Bodalski J. Iatrogenic hyperlipidemia after l-asparaginase and glucocorticoid treatment in two children with acute lymphoblastic leukemia. Pol Merkur Lekarski 2003;15:256-8. (article in Polish).
160. Athanassiadou F, Kourti M, Papageorgiou T, Stamou M, Makedou A, Boufidou A. Severe hyperlipidemia in a child with acute lymphoblastic leukemia treated with l-asparaginase and prednisone. Pediatr Int 2004;46:743-4.
161. Steinherz PG. Transient, severe hyperlipidemia in patients with acute lymphoblastic leukemia treated with prednisone and asparaginase. Cancer 1994;74:3234-9.
162. Iwamoto T, Kagawa Y, Naito Y, Kuzuhara S, Kojima M. Steroid-induced diabetes mellitus and related risk factors in patients with neurologic diseases. Pharmacotherapy 2004;24:508-14.
163. Markell MS, Friedman EA. Hyperlipidemia after organ transplantation. Am J Med 1989;87:61N-7N.
164. Deters M, Kirchner G, Koal T, Resch K, Kaever V. Everolimus/cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rates. Dig Dis Sci 2004;49:30-7.
165. Moghadasian MH. Dietary phytosterols reduce cyclosporine-induced hypercholesterolemia in apolipoprotein E-knockout mice. Transplantation 2006;81:207-13.
166. Lee MS. Cytokine synergism in apoptosis: its role in diabetes and cancer. J Biochem Mol Biol 2002;35:54-60.
167. Koivisto VA, Pelkonen R, Cantell K. Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes 1989;38:641-7.
168. Fabris P, Betterle C, Floreani A, et al. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 1992;340:548.
169. Tohda G, Oida K, Higashi S, Hayashi T, Miyamori I. Interferon-alpha and development of type 1 diabetes: a case without insulin resistance. Diabetes Care 1998;10:1774.
170. Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003;18:549-58.
171. Fabris P, Betterle C, Greggio NA, Zanchetta R, Bosi E, Biasin MR, et al. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol 1998;28:514-7.
172. Howard SC, Pui CH. Endocrine complications in pediatric patients with acute lymphoblastic leukemia. Blood Rev 2002;16:225-43.
173. Psarakis HM. Clinical challenges in caring for patients with diabetes and cancer. Diabetes Spectr 2006;19:157-62.
174. Ferner RE. Drug-induced diabetes. Baillieres Clin Endocrinol Metab 1992;6:849-66.
175. Schein PS, O, Connell MJ, Blom J, Hubbard S, Magrath IT, Bergevin P, et al. Clinical antitumor activity and toxicity of streptozocin (NSC-85998). Cancer 1974;34:993-1000.
176. Pavel ME, Baum U, Hahn EG, Hensen J. Doxorubicin and streptozocin after failed biotherapy for neuroendocrine tumors. Int J Gastrointest Cancer 2005;35:179-85.
177. Pandit MK, Burke J, Gustafson AB, Minocha A, Peiris AN. Drug-induced disorders of glucose tolerance. Ann Intern Med 1993;118:529-39.
178. Sestier C, Odent-Pogu S, Bonneville M, Maurel C, Lang F, Sai P. Cyclosporin enhances diabetes induced by low-dose streptozotocin treatment in mice. Immunol Lett 1985;10:57-60.
179. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alpha, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81.
180. Duran I, Le L, Saltman D, Singh W, Kocha R, Cheiken G, et al. A phase II trial of temsirolimus in metastatic neuroendocrine carcinomas (NECs, Abstract no: 146). 2005, Jan. 27-9. Gastrointestinal Cancers Symposium, Hollywood, FL, USA.
181. Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006;95:1148-54.
182. Ferrari S, Pieretti F, Verri E, Tolentinis L, Cedari M, Versari M, et al. Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cistplatin and high-dose methotrexate. Anticancer Drugs 2005;16:733-8.
183. Skinner R, Coterrill SJ, Stevens MC. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. Br J Cancer 2000;82:1636-45.
184. Feuerstein M, editor. Handbook of cancer survivorship. New York, Springer; 2007.